Company: ARVN
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049527
Chunk: 240

Company: ARVINAS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 240
---
16a-1(f) under the Exchange Act), engage in open-market transactions with respect to our securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.

Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in 

55

Table o    f Contents

our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.

None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this Quarterly Report on Form 10-Q.

Amended and Restated Employment Agreements

On November 4, 2025, we entered into amended and restated employment agreements with each of Angela Cacace, Ph.D., our Chief Scientific Officer, and Randy Teel, Ph.D., our Chief Business Officer. Each of Dr. Cacace and Dr. Teel is a named executive officer in our definitive proxy statement for our 2025 annual meeting of stockholders filed with the SEC on April 29, 2025, or our 2025 Proxy. 

The original employment agreements with each of Dr. Cacace and Dr. Teel were each entered into with us on January 2, 2019. The employment agreements for Dr. Cacace and Dr. Teel were amended and restated primarily so that the agreements would appropriately reflect the current title and level of compensation of each of Dr. Teel and Dr. Cacace, each as previously reported and detailed in our 2025 Proxy, in addition to certain other non-material updates.

56

Table o    f Contents

Item 6. Exhibits.

ExhibitNumberDescription3.1Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).3.2Second Amended and Restated By